← Back to Home

CAR T Therapy for Stiff Person Syndrome: 26-Patient Trial Shows Walking Improvements Sustained for One Year

After a single cell infusion, some patients who previously relied on walking aids could complete a walking test independently, and most had not resumed long-term immunotherapy. However, this small trial without a control group is not yet sufficient to establish long-term efficacy and risks.

By SURL BioNews

For people with stiff person syndrome, muscle stiffness and painful spasms can make even a short walk difficult. A trial of an experimental CAR T-cell therapy has shown signs of improvement lasting one year: of the 12 participants who initially needed walking aids to complete a walking test, eight could complete it without assistive devices one year after treatment. These results allow researchers to further explore whether a single intervention targeting the immune system could reduce the long-term burden of this rare neurological disease.

A team led by Amanda Piquet of the University of Colorado Anschutz School of Medicine presented one-year data from the KYSA-8 trial at the MSToronto 2026 meeting on October 21. The Phase 2 study, sponsored by Kyverna Therapeutics, enrolled 26 adults who had responded inadequately to at least one existing immunotherapy and used an open-label, single-arm design. Participants first received lymphodepleting treatment, followed by a single infusion of 100 million mivocabtagene autoleucel (miv-cel) CAR T cells. The one-year analysis in the conference poster had a data cutoff of July 10, 2026, with a median follow-up of 12 months.

The improvements were most directly reflected in walking ability. One year after treatment, the median reduction from baseline in the time needed to complete the Timed 25-Foot Walk was 49%; 20 of the 26 participants reached the threshold of at least a 20% reduction. The median increase in distance covered during the six-minute walk test was 119 meters. Improvements were also seen in muscle stiffness, sensitivity to stimuli, and disability scale scores, but completing a short-distance test without assistive devices does not mean that independence in all daily activities had been restored.

A reduced need for ongoing treatment was another outcome closely related to daily life. At one year, 24 participants, approximately 92%, were not receiving long-term immunotherapy for stiff person syndrome. The poster further explained that the other two participants received intravenous immunoglobulin after month eight, including one who resumed it while clinical benefits were still ongoing. This proportion therefore cannot be interpreted as meaning that all patients no longer needed medication, nor does it indicate a cure.

Miv-cel is made from patients’ own T cells, which are modified to recognize CD19 and thereby eliminate B cells carrying this marker. The study aims to achieve benefits beyond short-term symptom control by changing disease-related immune responses. The poster showed that B cells had reappeared in 17 participants within one year, while clinical improvements continued; among those with elevated GAD65-IgG antibodies before treatment, the median antibody reduction was 83%. These observations support further study of the relationship between immune system changes and treatment efficacy, but do not yet prove that the disease-causing immune response has permanently disappeared.

Alongside the efficacy signals, the treatment burden must also be weighed. The poster reported cytokine release syndrome in 92% of patients, all Grade 1 or 2, and immune effector cell-associated neurotoxicity syndrome in 12%, all Grade 1. The company separately reported that five participants developed Grade 3 or 4 neutropenia and three experienced treatment-related serious adverse events, all of which had resolved. The absence of high-grade cases of the immune reactions described above does not mean that the overall treatment course carries no serious risks.

These one-year data extend the observation period for the early improvements, but still come from an uncontrolled study of 26 participants. Patients and assessors knew that treatment had been given, and the study cannot distinguish the effects of treatment from those of disease fluctuations and other care factors in the way a randomized controlled trial could. The conference presentation provides a rationale for continued evaluation; more comprehensive research and long-term follow-up are still needed to determine which patients miv-cel may be suitable for, how long its benefits may last, and what less common or later-emerging risks it may carry.

References

  1. University of Colorado Anschutz
  2. Kyverna Therapeutics via GlobeNewswire
  3. Amanda L. Piquet et al., MSToronto 2026; hosted by Kyverna Therapeutics